
Two separate studies show that Merck & Co.'s and GlaxoSmithKline's human papillomavirus (HPV) vaccines appear highly effective in preventing cervical cancer, vulvar cancer, and genital warts.The recently completed trials involved Merck's Gardasil and GlaxoSmithKline's experimental vaccine. Earlier studies showed that Gardasil also protects against cervical intraepithelial neoplasia (CIN)-precancerous lesions that can develop into cervical cancer.
